A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer

被引:271
作者
Kirwan, JM
Symonds, P
Greene, JA
Tierney, J
Collingwood, M
Williams, CJ
机构
[1] Liverpool Womens Hosp, Liverpool L78 7SS, Merseyside, England
[2] Univ Leicester, Leicester Royal Infirm, Dept Clin Oncol, Leicester LE1 5WW, Leics, England
[3] Univ Liverpool, Dept Med, Liverpool L69 3GA, Merseyside, England
[4] MRC, Meta Anal Unit, Clin Trials Unit, London NW1 2DA, England
[5] Gynaecol Canc Collaborat, Inst Hlth Sci, Oxford OX3 7LF, England
[6] Inst Hlth Sci, Cochrane Gynaecol Canc Review Grp, Oxford OX3 7LF, England
关键词
SQUAMOUS-CELL CARCINOMA; RADIATION-THERAPY; CONCURRENT CHEMOTHERAPY; PELVIC RADIATION; RANDOMIZED-TRIAL; CISPLATIN; RADIOTHERAPY; COMPLICATIONS; METAANALYSES; PLATINUM;
D O I
10.1016/S0167-8140(03)00197-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: Concomitant chemoradiation (CRT) for locally advanced cervical cancer has become an established treatment based on randomised trials. Major concerns, however, remain over the acute and late toxicity and hence the generalisability of the conclusions of these studies. Materials and methods: A review of all known randomised trials using the Cochrane Collaboration methodology identified 19 trials (17 published, two unpublished) between 1981 and 2000 including 4580 randomised patients. Data on toxicity were available for 1766 patients. The trials differed in size, design, and accrual period. As a conceptual ranking, six grades of severity were used in all scales; groups 1-4 were combined to allow comparison of CRT and radiotherapy and expressed as an odds ratio. This systematic review examines the toxicity of the meta-analysis, with the cisplatin containing trials discussed separately. Results: Grade 1 and 2 haematological toxicities were higher in the CRT group. Significant differences were seen in grade 3 and 4 haematological and gastrointestinal toxicities where a twofold increase in white cell count [OR 2.15 CI 95% (1.57-2.95) P < 0.001], a threefold increase in platelet toxicity [OR 3.04 CI 95% (1.08-8.51) P = 0.005] and a twofold increase in gastrointestinal toxicity [OR 1.92 CI 95% (1.26-2.92) P < 0.001] were seen. Long-term toxicity was only described in eight trials, seven of which reported no statistical difference. Conclusions: In view of the consistency and extent of the survival benefit for CRT the additional acute toxicity appears to be acceptable. The lack of data on long-term toxicity needs to be addressed. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:217 / 226
页数:10
相关论文
共 47 条
[1]  
ARBUCK SG, 2001, REVISED COMMON TOXIC
[2]  
Arnott SJ, 1996, LANCET, V348, P1049
[3]   THE SIGNIFICANCE OF ANEMIA IN CLINICAL RADIATION-THERAPY [J].
BUSH, RS .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1986, 12 (11) :2047-2050
[4]   QUALITY-OF-LIFE DURING PELVIC RADIOTHERAPY [J].
BYE, A ;
OSE, T ;
KAASA, S .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1995, 74 (02) :147-152
[5]   EFFECT OF CIS-DICHLORODIAMMINE PLATINUM II AND X-RAYS ON MAMMALIAN-CELL SURVIVAL [J].
CARDE, P ;
LAVAL, F .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1981, 7 (07) :929-933
[6]  
Chalmers I., 1997, NONRANDOM REFLECTION, P231
[7]  
Chen HW, 1997, CHIN J CLIN ONCOL, V24, P249
[8]   RECTAL COMPLICATIONS IN PATIENTS WITH CARCINOMA OF THE CERVIX TREATED WITH CONCOMITANT CISPLATIN AND EXTERNAL-BEAM IRRADIATION WITH HIGH-DOSE-RATE BRACHYTHERAPY - A DOSIMETRIC ANALYSIS [J].
CLARK, BG ;
SOUHAMI, L ;
ROMAN, TN ;
EVANS, MDC ;
PLA, C .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 28 (05) :1243-1250
[9]  
Eifel Patricia J., 1994, International Journal of Radiation Oncology Biology Physics, V30, P212, DOI 10.1016/0360-3016(94)90727-7
[10]   TIME-COURSE AND INCIDENCE OF LATE COMPLICATIONS IN PATIENTS TREATED WITH RADIATION-THERAPY FOR FIGO STAGE IB CARCINOMA OF THE UTERINE CERVIX [J].
EIFEL, PJ ;
LEVENBACK, C ;
WHARTON, JT ;
OSWALD, MJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 32 (05) :1289-1300